



Model List of Essential Medicines

Abemaciclib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for [Other specified malignant neoplasms of breast](#)

Abiraterone [General information](#)

Section

Hormones and antihormones

◦ Oral > Solid: 250 mg; 500 mg

Indications

[Malignant neoplasms of prostate](#)

Adalimumab [General information](#)

Section

Immunomodulators for non-malignant disease

◦ Parenteral > General injections > SC: 40 mg per 0.8 mL; 40 mg per 0.4 mL; 10 mg per 0.2 mL; 20 mg per 0.4 mL

Indications

[Axial spondyloarthritis](#) [Crohn disease site](#) [Rheumatoid arthritis](#)

Afatinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for [Other specified malignant neoplasms of bronchus or lung](#)

All-trans retinoic acid [General information](#)

Section

Targeted therapies

◦ Oral > Solid: 10 mg capsule

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Allopurinol [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 500 mg (as sodium) powder for injection
- Oral > Solid: 100 mg; 300 mg

Indications

[Tumour lysis syndrome](#)



Anastrozole [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 1 mg tablet

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasms of breast](#)



Arsenic trioxide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)



Asparaginase [General information](#)

Section

Cytotoxic medicines

- Powder for injection: 10 000 IU in vial.
- Parenteral > General injections > unspecified: 10000 IU in vial powder for injection

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#)



Atezolizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 1.2 g per 20 mL concentrate solution for infusion
- Parenteral > General injections > IV: 840 mg per 14 mL in vial concentrate for solution for infusion; 1200 mg per 20 mL in vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of bronchus or lung](#) Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#) Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach](#) [Hepatocellular carcinoma of liver](#)



Axicabtagene ciloleucel [General information](#)

Section

Antineoplastics and supportive medicines

- Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

[Diffuse large B-cell lymphomas](#)



Axitinib [General information](#)

Section

Targeted therapies

- Oral > Solid > tablet: 1 mg; 3 mg; 5 mg

Indications

[Renal cell carcinoma of kidney, except renal pelvis](#)



Azacitidine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection

Indications

[Myeloid leukaemia](#)

Azathioprine [General information](#)

Section

Immunomodulators for non-malignant disease

- Oral > Solid > tablet: 50 mg (scored)
- Parenteral > General injections > IV: 50 mg in vial powder for injection (as sodium salt); 100 mg in vial powder for injection (as sodium salt)
- Oral > Liquid: 10 mg per mL
- Oral > Solid > tablet: 25 mg; 50 mg (scored)

Indications

[Relapsing-remitting multiple sclerosis](#) [Failure or rejection of transplanted organs or tissues](#)

Bendamustine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Follicular lymphoma](#)

Bevacizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion; 25 mg per mL in 16 mL vial concentrate for solution for infusion

Indications

[Hepatocellular carcinoma of liver](#)

Bicalutamide [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 50 mg

Indications

[Malignant neoplasms of prostate](#)

Binimetinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for [Other specified melanoma of skin](#)

Bleomycin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)

Indications

[Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Kaposi sarcoma of unspecified primary site](#) [Hodgkin lymphoma](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#)

Blinatumomab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 35 µg in vial; 38.5 µg in vial

Indications

[B lymphoblastic leukaemia or lymphoma, not elsewhere classified](#)

Bortezomib [General information](#)

Section

Targeted therapies

- Parenteral > General injections > unspecified: 3.5 mg in vial powder for injection

Indications

[Plasma cell myeloma](#)

Calcium folinate (leucovorin calcium) [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 15 mg tablet
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule
- Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule
- Oral > Solid > tablet: 15 mg; 5 mg; 25 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasm metastasis in large intestine](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant trophoblastic neoplasms of placenta](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#)

Capecitabine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid > tablet: 150 mg; 500 mg

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#)

Carboplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Other specified gliomas of brain](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasms of breast](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Other specified carcinomas of ovary](#) [Retinoblastoma](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Malignant neoplasms of cervix uteri](#) [Malignant neoplasms of hypopharynx](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasms of oropharynx](#)

Cemiplimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 7 mL vial concentrate for solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for [Other specified malignant neoplasms of bronchus or lung](#)
Therapeutic equivalent to [pembrolizumab](#) for [Adenocarcinoma of stomach](#) [Other specified malignant neoplasms of bronchus or lung](#)

Certolizumab pegol [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Chlorambucil [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 2 mg tablet

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)



Ciclosporin [General information](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > IV: 50 mg per mL in 1 mL ampoule concentrate for injection
- Oral > Liquid: 100 mg per mL
- Oral > Solid > capsule: 25 mg

Indications

[Failure or rejection of transplanted organs or tissues](#)



Cisplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection
- Parenteral > General injections > IV: 10 mg per 10 mL; 20 mg per 20 mL; 50 mg per 50 mL; 100 mg per 100 mL
- Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasms of nasopharynx](#) [Germ cell tumour of testis](#) [Malignant neoplasms of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of cervix uteri](#) [Malignant neoplasms of hypopharynx](#) [Malignant neoplasms of oropharynx](#) [Malignant neoplasms of nasopharynx](#)



Cladribine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial

Indications

[Langerhans cell histiocytosis](#)



Cobimetinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [trametinib](#) for [Other specified melanoma of skin](#)



Crizotinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 200 mg; 250 mg
- Oral > Solid > capsule: 200 mg; 250 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Cyclophosphamide [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 25 mg tablet
- Parenteral > General injections > unspecified: 500 mg in vial powder for injection
- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Oral > Solid > dosage form: 25 mg; 50 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasms of breast](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Plasma cell myeloma](#) [Other specified malignant neoplasms of breast](#) [Follicular lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant trophoblastic neoplasms of placenta](#) [Lymphoid leukaemia, not elsewhere classified](#) [Rhabdomyosarcoma primary site](#) [Hodgkin lymphoma](#) [Other specified gliomas of brain](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)

Cytarabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > unspecified: 100 mg in vial powder for injection
- Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)

Dabrafenib [General information](#)

Section

Targeted therapies

- Oral > Solid: 50 mg; 75 mg

Indications

[Other specified melanoma of skin](#)

Dacarbazine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection

Indications

[Hodgkin lymphoma](#)

Dactinomycin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 µg in vial powder for injection

Indications

[Malignant trophoblastic neoplasms of placenta](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Rhabdomyosarcoma primary site](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#)

Daratumumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 5 mL; 400 mg per 20 mL

Indications

[Plasma cell myeloma](#)

Darbepoetin alfa [General information](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Dasatinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 20 mg tablet; 50 mg tablet; 70 mg tablet; 80 mg tablet; 100 mg tablet; 140 mg tablet

Indications

[Chronic myeloid leukaemia, not elsewhere classified](#)



Daunorubicin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Lymphoid leukaemia, not elsewhere classified](#)
[Myeloid leukaemia](#)



Dexamethasone [General information](#)

Section

Hormones and antihormones

- Oral > Liquid: 2 mg per 5 mL
- Oral > Solid: 2 mg; 4 mg
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphate salt)
- Oral > Liquid: 2 mg per 5 mL (as sodium phosphate)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 2 mg (as dexamethasone base); 4 mg (as dexamethasone base)
- Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule dexamethasone phosphate (as sodium phosphate, equivalent to 3.3 mg/mL dexamethasone base)
- Oral > Solid > tablet: 4 mg (as dexamethasone base)

Indications

[Anaplastic large cell lymphoma, ALK-negative](#) [Lymphoid leukaemia, not elsewhere classified](#) [Plasma cell myeloma](#)
[Burkitt lymphoma including Burkitt leukaemia](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Docetaxel [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of prostate](#)
[Unspecified malignant neoplasms of ill-defined or unspecified sites](#)



Dostarlimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 10 mL vial concentrate for solution for infusion

Indications

[Other specified malignant neoplasms of corpus uteri](#)



Doxorubicin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)
- Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Rhabdomyosarcoma primary site](#) [Follicular lymphoma](#) [Malignant neoplasms of breast](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Hodgkin lymphoma](#) [Plasma cell myeloma](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Lymphoid leukaemia, not elsewhere classified](#) [Other specified malignant neoplasms of breast](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Kaposi sarcoma of unspecified primary site](#)



Doxorubicin (as pegylated liposomal) [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)

Indications

[Kaposi sarcoma of unspecified primary site](#)

Durvalumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 50 mg per mL in 2.4 mL vial concentrate solution for infusion; 50 mg per mL in 10 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#) [Malignant neoplasms of biliary tract, distal bile duct](#) [Malignant neoplasm of intrahepatic bile ducts](#) [Malignant neoplasms of gallbladder](#) [Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasms of proximal biliary tract, cystic duct](#)

Encorafenib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for [Other specified melanoma of skin](#)

Enzalutamide [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 40 mg

Indications

Therapeutic equivalent to [abiraterone](#) for [Malignant neoplasms of prostate](#) [Malignant neoplasms of prostate](#)

Epoetin alfa [General information](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Epoetin beta [General information](#)

Section

Supportive medicines

Indications

Therapeutic equivalent to [erythropoiesis-stimulating agents](#) for [Drug-induced aplastic anaemia](#)

Erlotinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 100 mg; 150 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#)

Erythropoiesis-stimulating agents [General information](#)

Section

Supportive medicines

- Parenteral > General injections > unspecified: 2000 IU per mL in vial (single-dose); 3000 IU per mL in vial (single-dose); 4000 IU per mL in vial (single-dose); 10000 IU per mL in vial (single-dose); 40000 IU per mL in vial (single-dose); 20000 IU per mL in vial (multiple-dose); 20000 IU per 2 mL in vial (multiple-dose)

Indications

[Drug-induced aplastic anaemia](#)

Etanercept [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)



Etoposide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule
- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)
- Oral > Solid: 100 mg capsule; 50 mg capsule

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Myeloid leukaemia](#) [Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Germ cell tumour of testis](#) [Malignant trophoblastic neoplasms of placenta](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Hodgkin lymphoma](#) [Retinoblastoma](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Everolimus [General information](#)

Section

Targeted therapies

- Oral > Solid > dispersible tablet: 2 mg; 3 mg; 5 mg
- Oral > Solid > tablet: 2.5 mg; 5 mg; 7.5 mg; 10 mg

Indications

[Other specified gliomas of brain](#)



Filgrastim [General information](#)

Section

Immunomodulators

- Parenteral > General injections > SC: 120 µg per 0.2 mL in prefilled syringe; 300 µg per 0.5 mL in prefilled syringe; 480 µg per 0.8 mL in prefilled syringe; 300 µg per mL in 1 mL vial; 480 µg per 1.6 mL in 1.6 mL vial

Indications

[Acquired neutropaenia](#)



Fingolimod [General information](#)

Section

Immunomodulators for non-malignant disease

- Oral > Solid: 0.25 mg; 0.5 mg

Indications

[Relapsing-remitting multiple sclerosis](#)



Fludarabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection
- Oral > Solid: 10 mg tablet (fludarabine phosphate)

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)



Fluorouracil [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule
- Parenteral > General injections > IV: 50 mg per mL in vial

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Malignant neoplasms of nasopharynx](#) [Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of rectum](#) [Malignant neoplasms of colon](#)

Flutamide [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [bicalutamide](#) for [Malignant neoplasms of prostate](#)

Fulvestrant [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > IV: 250 mg per 5 mL

Indications

[Malignant neoplasms of breast](#)

Gefitinib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [erlotinib](#) for [Other specified malignant neoplasms of bronchus or lung](#)

Gemcitabine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection

Indications

[Other specified carcinomas of ovary](#) [Other specified malignant neoplasms of bronchus or lung](#)

Golimumab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)

Goserelin [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of breast](#) Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of prostate](#)

Hydrocortisone [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > unspecified: 100 mg in vial (as sodium succinate)

Indications

[Lymphoid leukaemia, not elsewhere classified](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#)

Hydroxycarbamide (hydroxyurea) [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g

- Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg

Indications

[Squamous cell carcinoma of oropharynx](#) [Chronic myeloid leukaemia, not elsewhere classified](#)



Ibrutinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 140 mg

Indications

[Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)



Ifosfamide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection
- Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection

Indications

[Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Rhabdomyosarcoma primary site](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#)



Imatinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 100 mg; 400 mg

Indications

[B lymphoblastic leukaemia or lymphoma with t\(9:22\) \(q34;q11.2\); BCR-ABL1](#) [Chronic myeloid leukaemia, not elsewhere classified](#) [Gastrointestinal stromal tumour of unspecified gastrointestinal sites](#)



Infliximab [General information](#)

Section

Immunomodulators for non-malignant disease

Indications

Therapeutic equivalent to [adalimumab](#) for [Axial spondyloarthritis](#) Therapeutic equivalent to [adalimumab](#) for [Crohn disease site](#) Therapeutic equivalent to [adalimumab](#) for [Rheumatoid arthritis](#)



Ipilimumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 5 mg per mL in 10 mL vial concentrate for solution for infusion; 20 mg per mL in 40 mL vial concentrate for solution for infusion

Indications

[Renal cell carcinoma of kidney, except renal pelvis](#) [Squamous cell carcinoma of oesophagus](#) [Melanoma of skin](#) [Other specified malignant neoplasms of bronchus or lung](#)



Irinotecan [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial

Indications

[Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Rhabdomyosarcoma primary site](#)



Lenalidomide [General information](#)

Section

Immunomodulators
◦ Oral > Solid: 25 mg

Indications

[Plasma cell myeloma](#)



Lenvatinib [General information](#)

Section

Targeted therapies

- Oral > Solid > capsule: 4 mg; 10 mg

Indications

[Renal cell carcinoma of kidney, except renal pelvis](#)



Leuprorelin [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > IM: 7.5 mg in prefilled syringe; 22.5 mg in prefilled syringe

Indications

[Malignant neoplasms of breast](#) [Malignant neoplasms of prostate](#)



Lisocabtagene maraleucel [General information](#)

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for [Diffuse large B-cell lymphomas](#)



Melphalan [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection
- Oral > Solid: 2 mg

Indications

[Plasma cell myeloma](#)



Mercaptopurine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 50 mg tablet
- Oral > Liquid: 20 mg per mL

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Langerhans cell histiocytosis](#)



Mesna [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule
- Oral > Solid: 400 mg; 600 mg
- Parenteral > General injections > IV: 100 mg per mL in 4 mL ampoule; 100 mg per mL in 10 mL ampoule; 100 mg per mL in 2 mL ampoule
- Oral > Solid > tablet: 400 mg; 600 mg
- Oral > Other: 600 mg
- Oral > Solid > tablet: 400 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Osteosarcoma of bone and articular cartilage of other specified sites](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Rhabdomyosarcoma primary site](#)



Methotrexate [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial (as sodium salt)
- Oral > Solid: 2.5 mg (as sodium salt)
- Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Lymphoid leukaemia, not elsewhere classified](#) [Acute myeloid leukaemia with recurrent genetic abnormalities](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Malignant trophoblastic neoplasms of placenta](#) [Malignant neoplasms of breast](#) [Osteosarcoma of bone and articular cartilage of unspecified sites](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > SC: pre-filled syringe in multiple strengths

Indications

[Crohn disease site](#) [Psoriatic arthritis](#)



Methylprednisolone [General information](#)

Section

Hormones and antihormones

- Parenteral > General injections > IV: 40 mg in vial (as sodium succinate); 125 mg in vial (as sodium succinate)
- Parenteral > General injections > IV: 40 mg in vial (as sodium succinate) powder for injection; 125 mg in vial (as sodium succinate) powder for injection

Indications

[Burkitt lymphoma including Burkitt leukaemia](#) [Lymphoid leukaemia, not elsewhere classified](#)



Nilotinib [General information](#)

Section

Targeted therapies

- Oral > Solid > capsule: 150 mg; 200 mg

Indications

[Chronic myeloid leukaemia, not elsewhere classified](#)



Nilutamide [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [bicalutamide](#) for [Malignant neoplasms of prostate](#)



Nivolumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 10 mg per mL concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion; 10 mg per mL in 24 mL vial concentrate solution for infusion
- Parenteral > General injections > IV: 10 mg per mL in 24 mL vial concentrate solution for infusion; 10 mg per mL in 4 mL vial concentrate solution for infusion; 10 mg per mL in 10 mL vial concentrate solution for infusion; 10 mg per mL in 12 mL vial concentrate solution for infusion

Indications

Therapeutic equivalent to [pembrolizumab](#) for [Melanoma of skin](#) [Melanoma of skin](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Other specified malignant neoplasms of bronchus or lung](#) [Squamous cell carcinoma of oesophagus](#) [Adenocarcinoma of oesophagogastric junction](#) [Adenocarcinoma of stomach](#)



Osimertinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 40 mg (as mesylate); 80 mg (as mesylate)

Indications

[Other specified malignant neoplasms of bronchus or lung](#)



Oxaliplatin [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial

Indications

[Malignant neoplasm metastasis in large intestine](#) [Malignant neoplasms of colon](#)

Paclitaxel [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 6 mg per mL

Indications

[Other specified malignant neoplasms of the ovary](#) [Other specified malignant neoplasms of bronchus or lung](#) [Malignant neoplasms of nasopharynx](#) [Kaposi sarcoma of unspecified primary site](#) [Other specified malignant neoplasms of breast](#) [Other specified carcinomas of ovary](#) [Malignant neoplasms of breast](#) [Malignant neoplasms of cervix uteri](#)

Palbociclib [General information](#)

Section

Targeted therapies

- Oral > Solid: 75 mg; 100 mg; 125 mg

Indications

[Other specified malignant neoplasms of breast](#)

Panitumumab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 20 mg per mL in 5 mL vial concentrate for solution for infusion; 20 mg per mL in 20 mL vial

Indications

[Other specified malignant neoplasms of large intestine](#)

Pegaspargase [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection

Indications

[Lymphoid leukaemia, not elsewhere classified](#)

Pegfilgrastim [General information](#)

Section

Immunomodulators

- Parenteral > General injections > SC: 6 mg per 0.6 mL in pre-filled syringe

Indications

[Acquired neutropaenia](#)

Pembrolizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial powder for injection
- Parenteral > General injections > IV: 25 mg per mL in 4 mL vial concentrate for solution for infusion

Indications

[Melanoma of skin](#) [Other specified malignant neoplasms of large intestine](#) [Malignant neoplasms of cervix uteri](#) [Other specified malignant neoplasms of bronchus or lung](#) [Adenocarcinoma of stomach](#) [Malignant neoplasms of oesophagogastric junction](#) [Squamous cell carcinoma of hypopharynx and variants](#) [Squamous cell carcinoma of other or ill-defined sites in the lip, oral cavity or pharynx](#) [Squamous cell carcinoma of oropharynx](#) [Squamous cell carcinoma of nasopharynx](#) Therapeutic equivalent to [nivolumab](#) for [Melanoma of skin](#) [Renal cell carcinoma of kidney, except renal pelvis](#) [Carcinoma of breast, specialised type](#) [Squamous cell carcinoma of oesophagus](#)

Pertuzumab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 240 mg per 14 mL in vial concentrated solution

Indications

[Carcinoma of breast, specialised type](#)

Prednisolone [General information](#)

Section

Hormones and antihormones

- Oral > Liquid: 5 mg per mL
- Oral > Solid: 5 mg; 25 mg

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Follicular lymphoma](#) [Lymphoid leukaemia, not elsewhere classified](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Hodgkin lymphoma](#) [Plasma cell myeloma](#) [Malignant neoplasms of prostate](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)

Prednisone [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [prednisolone](#) for [Follicular lymphoma](#) Therapeutic equivalent to [prednisolone](#) for [Lymphoid leukaemia, not elsewhere classified](#) Therapeutic equivalent to [prednisolone](#) for [Diffuse large B-cell lymphoma, not otherwise specified](#) Therapeutic equivalent to [prednisolone](#) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) Therapeutic equivalent to [prednisolone](#) for [Hodgkin lymphoma](#) Therapeutic equivalent to [prednisolone](#) for [Plasma cell myeloma](#) Therapeutic equivalent to [prednisolone](#) for [Malignant neoplasms of prostate](#) Therapeutic equivalent to [prednisolone](#) for [Anaplastic large cell lymphoma, ALK-negative](#) Therapeutic equivalent to [prednisolone](#) for [Anaplastic large cell lymphoma, ALK-positive](#) Therapeutic equivalent to [prednisolone](#) for [Langerhans cell histiocytosis](#)

Procarbazine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 50 mg (as hydrochloride)
- Oral > Solid > capsule: 50 mg (as hydrochloride)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Hodgkin lymphoma](#)

Rasburicase [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 1.5 mg in vial powder and 1 mL solvent for solution; 7.5 mg in vial powder and 5 mL solvent for solution

Indications

[Tumour lysis syndrome](#)

Realgar-indigo naturalis formulation [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)

Indications

[Acute myeloid leukaemia with recurrent genetic abnormalities](#)

Ribociclib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [palbociclib](#) for [Other specified malignant neoplasms of breast](#)

Rituximab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg per 10 mL in 10 mL vial; 500 mg per 50 mL in 50 mL vial

Indications

[Follicular lymphoma](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#)

Tacrolimus [General information](#)

Section

Immunomodulators for non-malignant disease

- Parenteral > General injections > IV: 5 mg per mL in 1 mL vial
- Oral > Liquid: 0.2 mg granules for oral suspension; 1 mg granules for oral suspension
- Oral > Solid: 0.5 mg (immediate-release); 0.75 mg (immediate-release); 1 mg (immediate-release); 2 mg (immediate-release); 5 mg (immediate-release)

Indications

[Failure or rejection of transplanted organs or tissues](#)

Tamoxifen [General information](#)

Section

Hormones and antihormones

- Oral > Solid: 10 mg (as citrate); 20 mg (as citrate)

Indications

[Other specified malignant neoplasms of breast](#) [Malignant neoplasms of breast](#)

Temozolomide [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 100 mg in vial powder for injection
- Oral > Solid > capsule: 5 mg; 20 mg; 100 mg; 140 mg; 180 mg; 250 mg

Indications

[Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Other specified gliomas of brain](#) [Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Neuroblastoma, NOS](#)

Thalidomide [General information](#)

Section

Immunomodulators

- Oral > Solid: 50 mg

Indications

[Plasma cell myeloma](#)

Tioguanine [General information](#)

Section

Cytotoxic medicines

- Oral > Solid: 40 mg

Indications

[Lymphoid leukaemia, not elsewhere classified](#)

Tisagenlecleucel [General information](#)

Section

Antineoplastics and supportive medicines

Indications

Therapeutic equivalent to [axicabtagene ciloleucel](#) for [Diffuse large B-cell lymphomas](#)

Tislelizumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 100 mg per 10 mL
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion
- Parenteral > General injections > IV: 100 mg per 10 mL concentrate for solution for infusion

Indications

[Malignant neoplasms of urinary tract](#) [Hodgkin lymphoma](#) [Other specified malignant neoplasms of bronchus or lung](#)
[Squamous cell carcinoma of oesophagus](#)

Toripalimab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 240 mg per 6 mL in vial

Indications

[Malignant neoplasms of nasopharynx](#) [Squamous cell carcinoma of oesophagus](#)

Trametinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 0.5 mg; 2 mg

Indications

[Other specified melanoma of skin](#)

Trastuzumab [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 60 mg in vial powder for injection; 150 mg in vial powder for injection; 440 mg in vial powder for injection

Indications

[Carcinoma of breast, specialised type](#)

Trastuzumab emtansine [General information](#)

Section

Targeted therapies

- Parenteral > General injections > IV: 100 mg in vial powder for injection; 160 mg in vial powder for injection

Indications

[Carcinoma of breast, specialised type](#)

Tremelimumab [General information](#)

Section

Immunomodulators

- Parenteral > General injections > IV: 20 mg per mL in 1.25 mL vial concentrate solution for infusion; 20 mg per mL in 15 mL vial concentrate solution for infusion

Indications

[Hepatocellular carcinoma of liver](#) [Other specified malignant neoplasms of bronchus or lung](#)

Triptorelin [General information](#)

Section

Hormones and antihormones

Indications

Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of breast](#) Therapeutic equivalent to [leuprorelin](#) for [Malignant neoplasms of prostate](#)

Vemurafenib [General information](#)

Section

Targeted therapies

Indications

Therapeutic equivalent to [dabrafenib](#) for [Other specified melanoma of skin](#)



Vinblastine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate)
- Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Hodgkin lymphoma](#) [Other specified malignant neoplasms of the ovary](#) [Germ cell tumour of testis](#) [Kaposi sarcoma of unspecified primary site](#) [Anaplastic large cell lymphoma, ALK-negative](#) [Anaplastic large cell lymphoma, ALK-positive](#) [Langerhans cell histiocytosis](#)



Vincristine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)
- Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)

Indications

[Unspecified malignant neoplasms of ill-defined or unspecified sites](#) [Other specified gliomas of brain](#) [Follicular lymphoma](#) [Malignant trophoblastic neoplasms of placenta](#) [Diffuse large B-cell lymphoma, not otherwise specified](#) [Kaposi sarcoma of unspecified primary site](#) [Rhabdomyosarcoma primary site](#) [Hodgkin lymphoma](#) [Burkitt lymphoma including Burkitt leukaemia](#) [Ewing sarcoma of bone and articular cartilage of unspecified sites](#) [Malignant neoplasms of kidney, except renal pelvis](#) [Lymphoid leukaemia, not elsewhere classified](#) [Retinoblastoma](#) [Langerhans cell histiocytosis](#)



Vinorelbine [General information](#)

Section

Cytotoxic medicines

- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial
- Oral > Solid > capsule: 20 mg; 30 mg; 80 mg

Indications

[Other specified malignant neoplasms of bronchus or lung](#) [Other specified malignant neoplasms of breast](#) [Rhabdomyosarcoma primary site](#)



Zanubrutinib [General information](#)

Section

Targeted therapies

- Oral > Solid: 80 mg
- Oral > Solid > capsule: 80 mg

Indications

[Mantle cell lymphoma](#) [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#) Therapeutic equivalent to [ibrutinib](#) for [Chronic lymphocytic leukaemia or small lymphocytic lymphoma](#)



Zoledronic acid [General information](#)

Section

Supportive medicines

- Parenteral > General injections > IV: 4 mg per 5 mL in 5 mL vial; 4 mg per 100 mL in 100 mL bottle

Indications

[Malignant neoplasm metastasis in bone or bone marrow](#)